Dihexa and 'synaptic rewiring': what the hype gets wrong

What's this video probably claiming?

Based on the caption and hashtags, @cognifluxx is likely positioning Dihexa as a next-generation nootropic capable of physically restructuring brain synapses to improve memory, learning speed, and general cognitive performance. The framing around "rewiring the brain at the synaptic level" and tagging #iq and #mogged (a term common in male self-optimization communities) suggests the video is pitching Dihexa as a cognitive edge, possibly comparing it favorably to established compounds or implying it can measurably raise intelligence. The "experimental science" framing gives it a veneer of credibility while sidestepping the obvious problem: almost everything known about Dihexa comes from rodent studies, not human trials. Expect claims about HGF/c-Met pathway activation, synaptogenesis, and possibly comparisons to other peptides in the nootropic space like Semax or Selank.

What does the science actually show?

Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) was developed at Washington State University and is a potent hepatocyte growth factor (HGF) agonist. The most-cited work comes from McCoy et al. (2013, Journal of Pharmacology and Experimental Therapeutics), where the compound showed roughly 10 million times greater potency than BDNF in promoting synaptogenesis in vitro. That sounds extraordinary, and the biohacking crowd has run with it. But in vivo rodent data from the same lab showed improved Morris Water Maze performance in scopolamine-induced cognitive impairment models, not healthy animals. The distinction matters enormously. There are no published Phase I, II, or III human clinical trials for Dihexa as of 2024. Zero. The jump from "fixes chemically-induced amnesia in rats" to "rewires your brain for higher IQ" is not a small inferential leap. It is a chasm.

Where does the social media noise diverge from clinical reality?

The #biohacking and #nootropic communities treat rodent data as a menu, not a warning label. Dihexa gets discussed on forums and TikTok as if synaptogenesis in a dish translates directly to cognitive enhancement in a healthy 24-year-old. It does not, and there are reasons to be cautious beyond the missing human data. HGF/c-Met signaling is implicated in tumor growth and progression. Researchers including Matsumoto & Nakamura (2006, Journal of Gastroenterology) have documented c-Met pathway involvement in hepatocellular carcinoma and other cancers. A compound that is a potent, long-acting HGF agonist, with no known half-life data in humans, no safety profile from trials, and no established dosing range, being self-administered based on TikTok content is not biohacking. It is uncontrolled self-experimentation with an unknown risk-benefit ratio.

What should you actually know?

Dihexa is not approved by the FDA for any indication. It is not a regulated supplement. It exists in a grey market similar to other research peptides, sold by vendors with varying quality controls and no accountability for what is actually in the product. The compound's potential is scientifically interesting. McCoy's team has done real work worth watching. But "potentially interesting in animal models" and "safe and effective for human use" are separated by years of clinical investigation that has not happened yet. If you are considering any peptide for cognitive support, the compounds with the most actual human data, like Semax (Russian clinical literature going back to the 1990s) or even well-studied racetams, are a significantly different proposition than Dihexa. The #mogged framing also warrants calling out directly: intelligence is not a peptide-responsive variable in healthy individuals based on current evidence. Anyone telling you otherwise has a product to sell.